S těhotenstvím související adenokarcinom plic s mutací EGFR v oblasti s endemickým výskytem tuberkulózy –⁠ diagnostická zkreslení a terapeutické překážky

Download PDF English version

Authors: Dr. Muhammad Hafiz, SpP ^1,2; Prof. Dr. Aziza G. Icksan ³; Dr. Ph. Sita Laksmi Andarini D, Ph.D, SpP ^1,4,5; Dr. Nur M Karim, SpR ⁶; Dr. Annisa Dian Hari Hasari, SpP ²; Farhana Ibrahim Syuaib, MD ^4,5; Dr. Retno Widyawati, SpPA ⁷; Dr. Tati Herdawati, SpPA ⁷
Authors‘ workplace: Lung Cancer Center, MRCCC Siloam Hospitals Semanggi, Jakarta, Indonesia ¹; Department of Pulmonology and Respiratory Medicine, Budhi Asih General Hospital, Jakarta, Indonesia ²; Department of Radiology, Universitas PRIMA, Medan, Indonesia ³; Division of Thoracic Oncology, Department of Pulmonology and Respiratory Medicine, Persahabatan Hospital, Jakarta, Indonesia ⁴; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia ⁵; Department of Radiology, Budhi Asih General Hospital, Jakarta, Indonesia ⁶; Department of Anatomical Pathology, Budhi Asih General Hospital, Jakarta, Indonesia ⁷
Published in: Klin Onkol 2026; 39(5): 372-377
Category:
doi: https://doi.org/10.48095/ccko2026372

...

Sources

1. Jänne PA, Planchard D, Kobayashi K et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 2026; 394 (1): 27–38. doi: 10.1056/nejmoa2510308.

2. Hendriks LE, Kerr KM, Menis J et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (4): 339–357. doi: 10.1016/j.annonc.2022.12.009.

3. Cho BC, Lu S, Felip E et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 2024; 391 (16): 1486–1498. doi: 10.1056/nejmoa2403614.

4. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25): 2380–2388. doi: 10.1056/NEJMoa0909530.

5. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3): 239–246. doi: 10.1016/S1470-2045 (11) 70393-X.

6. Ocran Mattila P, Ahmad R, Hasan SS et al. Availability, affordability, access, and pricing of anti-cancer medicines in low -⁠ and middle-income countries: a systematic review of literature. Front Public Health 2021; 9 : 628744. doi: 10.3389/fpubh.2021.628744.

7. Bamodu OA, Chung CC. Cancer care disparities: overcoming barriers to cancer control in low -⁠ and middle--income countries. JCO Glob Oncol 2024; 10: e2300439. doi: 10.1200/GO.23.00439.

8. Amanda G, Susanto AD, Soehardiman D et al. Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy. Lung India 2017; 34 (6): 548–551. doi: 10.4103/0970-2113.217574.

9. Zhou JP, Wang Y, Lin YN et al. Clinical features and management of lung cancer during pregnancy: a narrative review based on reported cases. Womens Health Rep (New Rochelle) 2023; 4 (1): 544–550. doi: 10.1089/whr.2023.0085.

10. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974; 185 (4157): 1124–1131. doi: 10.1126/science.185.4157.1124.

11. Revannasiddaiah S, Madabhavi I, Thakur P et al. Undue delay in the diagnosis of lung cancer due to the clinician’s preoccupation with pre-existing tuberculosis. BMJ Case Rep 2011; 2011: bcr1020114932. doi: 10.1136/bcr.10.2011.4932.

12. Boussios S, Han SN, Fruscio R et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer 2013; 82 (3): 499–505. doi: 10.1016/j.lungcan.2013.09.002.

13. Yang L, He YT, Kang J et al. Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer. J Thorac Dis 2021; 13 (7): 4125–4136. doi: 10.21037/jtd-21-234.

14. Simons E, Camidge DR. Lung cancer oncogene-directed therapy, fertility, and pregnancy. J Thorac Oncol 2024; 19 (6): 866–876. doi: 10.1016/j.jtho.2024.01.003.

15. Mok TS, Kim SW, Wu YL et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation–positive non–small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol 2017; 35 (36): 4027–4034. doi: 10.1200/JCO.2017.73.9250.